Project Grant HT94252510188
Award Date
4/15/25
Completion Date
4/14/28
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...
The U.S. Defense Health Agency awarded Arizona State University a $1,103,084 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to develop a personalized blood-based diagnostic assay for the early detection of amyotrophic lateral sclerosis (ALS). The award period runs from November 1, 2024 to October 31, 2026.
As a sub-awardee, Georgetown University will also contribute to the project's research and development activities. The Department of Defense is...
The Regents of the University of California, San Francisco (UCSF) was awarded a $786,674 Project Grant from the Defense Health Agency through the Military Medical Research and Development program to identify RNA processing factors that restore expression of motor neuron-enriched genes in amyotrophic lateral sclerosis (ALS). The two-year award beginning August 1, 2023 will support UCSF's research efforts to investigate medical solutions for ALS on the cellular level through exploring the role...
This federal Project Grant award, issued by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), provides $963,000.00 to The Regents of the University of California, doing business as University of California, Berkeley, to conduct research on "REBALANCING C9ORF72 LOSS OF FUNCTION IN AMYOTROPHIC LATERAL SCLEROSIS". The research, which will take place over a two-year period from March 1, 2024 to February 28, 2026, aims to...
This Project Grant award of $498,828.00 from the Defense Health Agency supports the development of a novel treatment strategy and unique methods of delivery to the central nervous system for amyotrophic lateral sclerosis (ALS). The award, effective from July 1, 2023 to June 30, 2025, is funded through the Military Medical Research and Development program (CFDA 12.420), which focuses on transforming health care for Service Members and the public through innovative and impactful biomedical...
This federal Project Grant award in the amount of $2,490,000.00, awarded by the Defense Health Agency on March 1, 2025, supports the development of a VAV2 antisense oligonucleotide therapeutic for Amyotrophic Lateral Sclerosis (ALS) at the University of Southern California (USC). The award, funded under the CFDA 12.420 Military Medical Research and Development program, enables USC to conduct innovative biomedical research to advance treatments for this debilitating neurodegenerative disease...
This federal Project Grant award of $1,072,079.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the Massachusetts Institute of Technology (MIT) to develop diagnostic biomarkers for clinical subtypes of amyotrophic lateral sclerosis (ALS). The research aims to advance the understanding and treatment of ALS, a neurological disorder, with potential benefits for military service members and the broader public....
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance...
This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $894,330.00 to the University of Miami to conduct research on "TARGETING AXONAL REGENERATION PATHWAYS AS A THERAPEUTIC APPROACH TO ALS." The two-year award, running from February 1, 2025 to January 31, 2027, will support the university's specialized expertise in biomedical research, clinical trials, and healthcare studies to investigate...
The Defense Health Agency awarded a $1,210,500 Project Grant to Mayo Clinic under the Military Medical Research and Development program (CFDA 12.420) to explore novel biomarkers for amyotrophic lateral sclerosis (ALS) using a multiomics approach. The grant, which runs from April 1, 2025 to March 31, 2028, will support research aimed at developing improved methods for detecting and monitoring ALS progression, including utilizing immunoprofiling, extracellular vesicle analysis, and TDP-43...